Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease

NCT02484755 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Cushing's Disease
Corticotrophin Adenoma

Interventions

DRUG: Gefitinib

Sponsor

Huashan Hospital